Working… Menu

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04056117
Recruitment Status : Recruiting
First Posted : August 14, 2019
Last Update Posted : September 9, 2019
Kenya Medical Research Institute
KEMRI-Wellcome Trust Collaborative Research Program
Information provided by (Responsible Party):
LimmaTech Biologics AG

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : January 2022